Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries.
Bunka telling Proactive the deal is for research and development that will investigate Lexaria's technology for potential use in nicotine products. All costs of the research will be covered by British American Tobacco.